Qiagen Shares Jump Over 10% on Potential $50-Per-Share Takeover Interest
QGEN•Qiagen shares surged over 10% to four-month intraday highs on market speculation of bids at least $50 per share, implying a 16% premium. The company has engaged Moelis & Co. and Goldman Sachs to review strategic options and carries a $44.46 12-month consensus price target.
1. Shares Surge on Takeover Speculation
Qiagen shares surged over 10% to four-month intraday highs on market speculation that private equity firms may bid at least $50 per share, roughly a 16% premium to the prior closing price.
2. Strategic Review Underway
The company has engaged Moelis & Co. and Goldman Sachs to conduct a strategic review initiated in March, as Qiagen explores options to maximize shareholder value amid renewed acquisition interest.
3. Analyst Valuation and Outlook
Qiagen’s 12-month consensus price target stands at $44.46 from 15 analysts, with recent upgrades—including Morgan Stanley’s move to Overweight and a $42 target—highlighting bullish sentiment ahead of any formal bid.
